Who Paid My Doc
Richard Wang
Medical Toxicology Atlanta, GA Doctor of Osteopathy
NPI 1720037161 CMS profile 214277
550 Peachtree St., Department Of Emergency Medicine, Ground Floor, Atlanta, GA 30308
General payments
$29
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Richard Wang of Atlanta, GA is reported in the CMS Open Payments database as having received $29 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $29 | 1 |
Beside peers
- Richard Wang
- Medical Toxicology median
- Middle half of Medical Toxicology
- National median
In program year 2025, general payments to Richard Wang were reported at $0. Among 30 Medical Toxicology profiles paid that year, the median was $105 and the middle half received between $44 and $290.
Show as a table
| Year | Richard Wang | Medical Toxicology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $110 | $28–$420 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $0 | $41 | $18–$123 | $149 |
| 2023 | $0 | — | — | $160 |
| 2024 | $29 | $78 | $26–$128 | $164 |
| 2025 | $0 | $105 | $44–$290 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
21
Drug cost
$87
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 21 | $87 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$10,425
Medicare patients
73
Services billed
84
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Diabetes | 40% | |
| Chronic kidney disease | 37% | |
| Heart failure | 30% | |
| Ischemic heart disease | 26% | |
| COPD | 25% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Medical Toxicology in Georgia
Related records
Medical Toxicology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Medical Toxicology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.